fingolimod hydrochloride has been researched along with Arteriosclerosis, Coronary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ching, D; Eberlé, D; Honbo, N; Imhof, I; Karliner, JS; Kim, RY; Kumar, N; Li, K; Luk, FS; Raffai, RL; Wang, G; Zhu, BQ | 1 |
| Halank, M; Schrötter, H; Thomas, K; Ziemssen, T | 1 |
| Gutkind, S; Hla, T; Hwa, J; Obinata, H; Okuno, T; Stitham, J; Yokomizo, T | 1 |
| Ching, D; Honbo, N; Hoover, H; Imhof, I; Joshi, SK; Karliner, JS; Kim, RY; Li, K; Lovett, DH; Luk, FS; Raffai, RL; Wong, DK; Zhu, BQ | 1 |
| Furukawa, Y; Hara, M; Hwang, MW; Iwasaki, A; Matsumori, A; Okada, M; Ono, K; Sasayama, S | 1 |
5 other study(ies) available for fingolimod hydrochloride and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction.
Topics: Animals; Apolipoproteins E; Cardiotonic Agents; Coronary Artery Disease; Diet, High-Fat; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Propylene Glycols; Sphingosine; Survival Rate; T-Lymphocytes, Regulatory; Time Factors; Transforming Growth Factor beta; Ventricular Function, Left | 2014 |
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
Topics: Coronary Artery Disease; Female; Fingolimod Hydrochloride; Heart Failure; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2014 |
Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.
Topics: Aged; Animals; Case-Control Studies; Cell Line; Cells, Cultured; Coronary Artery Disease; Cricetulus; Drug Resistance; Endocytosis; Female; Fingolimod Hydrochloride; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; Lysophospholipids; Male; Middle Aged; Mutant Proteins; Polymorphism, Single Nucleotide; Propylene Glycols; Receptors, Lysosphingolipid; Recombinant Fusion Proteins; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2014 |
Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis.
Topics: Animals; Apolipoproteins E; Coronary Artery Disease; Diet, High-Fat; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Mice; Mice, Transgenic; Myocardial Infarction; Scavenger Receptors, Class B; Survival Rate | 2016 |
FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.
Topics: Animals; Coronary Artery Disease; Cyclosporine; Disease Progression; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Postoperative Complications; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 1999 |